Search results for "Letter to Editor"

showing 7 items of 7 documents

Arthritis Associated with Ulcerative Colitis: Our Experience in Palermo

2009

To The Editor: Ulcerative colitis (UC) is one of the inflammatory bowel diseases, which affects the small intestine and colon [1]. The pathophysiology of UC is not known [2, 3]. The association between arthritis and UC is well known. The authors report the frequency of arthritis in 53 Sicilian patients with UC. The diagnosis of UC was made according to criteria described by Schachter and Kirsner [4]. The involvement of sacroilitic joints was assessed radiologically according to Bennett and Burch grade (0=normal joint, 1=suspicious sacroiliitis 2=abnormal joint with sclerosis and/or erosions, 3=unequivocally abnormal with erosions, sclerosis, widening or narrowing or partly ankylosed, 4=tota…

musculoskeletal diseasesmedicine.medical_specialtylcsh:MedicineArthritisLetter to EditorGastroenterologyInternal medicineSettore MED/33 - Malattie Apparato LocomotoremedicineAnkylosisRheumatoid factorSpondylitisHLA-B27Inflammatory bowel diseases Arthritis spondylitis ulcerative colitisbusiness.industryArthritislcsh:RSacroiliitisGeneral MedicineInflammatory Bowel Diseasesmedicine.diseaseUlcerative colitisSurgerymedicine.anatomical_structureUlcerative colitisAnklebusinessSpondylitisLibyan Journal of Medicine
researchProduct

Doege-Potter syndrome: When seizures and hypoglycemia collide.

2018

Reactive HypoglycemiaSeizuresInsulin-Like Growth FactorsElectroencephalographySolitary Fibrous Tumor of the PleuraLetter to EditorHypoglycemiaIranian journal of neurology
researchProduct

A case of cefditoren‐induced Acute Generalized Exanthematous Pustulosis during COVID‐19 pandemics. Severe Cutaneous Adverse Reactions (SCARs) are an …

2020

Abstract We read with interest the article by Recalcati et al. about the report of cutaneous manifestations in COVID‐19 patients. We would like to highlight that some potentially severe manifestations in these patients are not directly related to the coronavirus but to the medications administered.

0301 basic medicine2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)030106 microbiologyDermatologymedicine.disease_causeLetter to EditorSARS‐CoV‐2030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineCOVID‐19PandemicSeverity of illnessmedicineSevere Cutaneous Adverse Reactions (SCARs)Coronavirusbusiness.industryFollow up studiesAcute Generalized Exanthematous Pustulosis (AGEP)Acute generalized exanthematous pustulosismedicine.diseaseDermatologyInfectious DiseasesbusinessCefditorenmedicine.drugJournal of the European Academy of Dermatology and Venereology
researchProduct

Tuning gut microbiota through a probiotic blend in gemcitabine‐treated pancreatic cancer xenografted mice

2021

Medicine (General)Transplantation HeterologousMedicine (miscellaneous)Gut floraSettore MED/08 - Anatomia PatologicaDeoxycytidineLetter to Editorlaw.inventionProbioticMiceR5-920lawPancreatic cancermedicineAnimalsbiologybusiness.industryProbioticsbiology.organism_classificationmedicine.diseaseGemcitabineGemcitabineGastrointestinal Microbiomegut microbiota gemcitabine pancreatic cancer xenografted micePancreatic NeoplasmsCancer researchMolecular Medicinebusinessmedicine.drugClinical and Translational Medicine
researchProduct

Cutaneous manifestations in COVID‐19: a new contribution

2020

Abstract We have read with great interest Dr Recalcati’s review about skin manifestations in COVID‐19 as it is the first report on this subject1. In a recent review on clinical characteristics of coronavirus disease 2019 in China, rash was observed in 0,2% of cases2. However, from the trained eyes of a dermatologist, this percentage may be higher.

2019-20 coronavirus outbreakmedicine.medical_specialtyskinCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DermatologyLetter to Editor030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineCOVID‐19medicineSkin manifestationscutaneous manifestationsbusiness.industrycutaneousmedicine.diseaseDermatologyRashPneumoniaInfectious Diseases030220 oncology & carcinogenesisDifferential diagnosismedicine.symptombusinessCoronavirus InfectionsJournal of the European Academy of Dermatology and Venereology
researchProduct

Atypical thrombosis associated with VaxZevria (R) (AstraZeneca) vaccine: Data from the French Network of Regional Pharmacovigilance Centres

2021

The current COVID-19 pandemic is an exceptional health situation including for drug use. As there was no known effective drug for COVID-19 at the beginning of the pandemic, different candidates were proposed. In this short article, we present the French public pharmacovigilance activities during this health crisis. Although COVID-19 is a confounding factor per se, owing to its potential for multi-organ damage including the heart and kidney, the quality of the transmitted data in adverse drug reaction reports, the timeliness of feedback from clinicians, and the real-time pharmacological and medical analysis by the French network of the regional pharmacovigilance centers made it possible to s…

2019-20 coronavirus outbreakTime FactorsCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[SDV]Life Sciences [q-bio]Letter to EditorAntiviral AgentsPharmacovigilancePharmacovigilancemedicineAdverse Drug Reaction Reporting SystemsHumansPharmacology (medical)PandemicsComputingMilieux_MISCELLANEOUSCovid-19 vaccineSARS-CoV-2business.industryCOVID-19VaxZevria®medicine.diseaseAtypical thrombosisThrombosisVirology[SDV] Life Sciences [q-bio]Anti-PF4 antibodiesFrancebusinessThrombopenia
researchProduct

The oral KIF11 inhibitor 4SC‐205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma …

2021

Inhibidor de KIF11; Terapias dirigidas; Metástasis Inhibidor de KIF11; Teràpies dirigides; Metàstasi KIF11 inhibitor; Targeted therapies; Metastasis In summary, our study provides a rationale for the future therapeutic integration in clinical trials of 4SC-205, an structurally distinct oral KIF11 inhibitor that shows potent antitumor activity in multiple preclinical neuroblastoma models and sensitizes neuroblastoma cells to standard chemotherapy and specific neuroblastoma-targeted therapies. The financial support for this research was provided by Instituto de Salud Calos III (PI20/00530 to Miguel F. Segura; PI20/01107 to Rosa Noguera; PI17/02248 and CPII18/00027 to Anna Santamaria; PI19/013…

Medicine (General)Neuroblastoma - Tractament:neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::neoplasias neuroepiteliales::tumores neuroectodérmicos primitivos::tumores neuroectodérmicos primitivos periféricos::neuroblastoma [ENFERMEDADES]Metastatic neuroblastomaMedicació oralMedicaments antineoplàstics - Ús terapèutic:Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]Medicine (miscellaneous)Administration OralKinesinsAntineoplastic Agents:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Letter to Editor:Neoplasms::Neoplasms by Histologic Type::Neoplasms Germ Cell and Embryonal::Neuroectodermal Tumors::Neoplasms Neuroepithelial::Neuroectodermal Tumors Primitive::Neuroectodermal Tumors Primitive Peripheral::Neuroblastoma [DISEASES]MiceNeuroblastomaR5-920Cell Line Tumor:terapéutica::farmacoterapia::vías de administración de medicamentos::administración oral [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]MedicineAnimalsHumansAntitumor activityPrimary (chemistry)business.industry:acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos [COMPUESTOS QUÍMICOS Y DROGAS]Disease Models Animal:Therapeutics::Drug Therapy::Drug Administration Routes::Administration Oral [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Cancer researchMolecular Medicine:Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [CHEMICALS AND DRUGS]businessClinical and Translational Medicine
researchProduct